Compare RGEN & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | BIO |
|---|---|---|
| Founded | 1981 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.7B |
| IPO Year | N/A | N/A |
| Metric | RGEN | BIO |
|---|---|---|
| Price | $158.82 | $311.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $177.18 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 600.1K | 185.7K |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $707,890,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $17.86 | $1.62 |
| Revenue Next Year | $12.44 | $2.26 |
| P/E Ratio | $6,367.21 | ★ N/A |
| Revenue Growth | ★ 11.74 | N/A |
| 52 Week Low | $102.97 | $211.43 |
| 52 Week High | $182.52 | $373.69 |
| Indicator | RGEN | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 48.61 |
| Support Level | $158.80 | $316.57 |
| Resistance Level | $165.30 | $328.56 |
| Average True Range (ATR) | 6.12 | 8.78 |
| MACD | -0.95 | 0.11 |
| Stochastic Oscillator | 22.13 | 45.52 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.